Tests ontunisertib against placebo in adults with narrowed bowel from Crohn's disease
Tests ontunisertib against placebo in adults with narrowed bowel from Crohn's disease.
Key facts
- Who runs it
- Agomab Spain S.L.U.
- Where
- Albany, Bradenton, Cedar Park, Fort Worth, Georgetown, Providence, and Sun City, United StatesSee the 7 sitesAlso in 2 other countries, 4 sites
- Trial code
- Registry title
- NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 320 people, planned
- Started
- 30 Oct 2026
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional, 4 groups
- Treatments tested
- Ontunisertib
- Placebo
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease who have a narrowed section of the bowel (stricture) that causes symptoms. It tests ontunisertib against placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Crohn's disease of the ileum or ileum and colon, diagnosed at least 12 weeks before signing consent. At least 1 ileal stricture that a scope cannot pass, confirmed by MRE. Blockage symptoms and/or diet limits.
- Earlier treatment
- Must be on a stable anti-inflammatory treatment for Crohn's disease and agree to keep it unchanged. No balloon widening or surgery of the stricture in the last 6 months.
Main reasons for not taking part
- Ulcerative colitis or other types of colitis
- Crohn's complications such as short bowel, stoma, internal fistulae or an untreated abscess
- Heart valve problems or left ventricular ejection fraction below 50%
- Expected to need hospital stay, balloon widening, surgery or changed treatment in the first 4 weeks
- Body mass index below 18 or 35 and above
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Diagnosis of ileal or ileocolonic CD based on clinical and endoscopic or radiological evidence established at least 12 weeks prior to signing the ICF
- Presence of at least 1 endoscopically non-passable ileal stricture
- Present stricture(s) can be naïve or anastomotic, and will be confirmed by centrally read MRE
- Presence of (sub)obstructive symptoms AND/OR dietary restrictions like limiting the amount or type of food, and/or food processing methods
- Participants should be on stable anti-inflammatory background therapy for CD and agree to maintain stable background therapy for the duration of the trial
- Participants should have a body mass index ≥18 kg/m2 and <35 kg/m2
- Not expected in the investigator's opinion to require hospitalization, endoscopic balloon dilation, surgical resection, or optimized anti-inflammatory therapy during the first 4 weeks of the trial
Who cannot take part
- History or current diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug-induced colitis, idiopathic colitis (i.e., colitis not consistent with CD), radiation colitis, microscopic colitis, colonic mucosal dysplasia, untreated bile acid malabsorption, or infectious colitis
- Endoscopic balloon dilation or surgical treatment of the index small bowel stricture within the last 6 months prior to screening
- CD-related complications:; Short bowel syndrome (<200 cm small bowel remaining); Ileostomy (diverting or end), colostomy, small bowel stoma, or ileoanal pouch; Internal fistulae and sinus tracts deriving from the area of stenosis. Participants with perianal fistulae could be included if not septic; Anal and perianal stricture; Suspected or diagnosed active intra-abdominal or perianal abscess that has not been appropriately treated and abscess in relation to the stricture; Toxic megacolon; Blind-ending sinus could be included
- Current or history of valvulopathy, or moderate or severe heart valve function defect, including moderate or severe valve stenosis or regurgitation OR left ventricular ejection fraction <50% as assessed locally through echocardiography
- Any other severe acute or chronic medical condition, psychiatric disorder, laboratory abnormality, or systemic or opportunistic infection that may increase the risk associated with trial participation or trial treatment administration, or may interfere with the interpretation of trial results, as determined by the investigator
- Clinically significant abnormal vital signs, physical examination, or abnormalities at 12-lead ECG at screening or baseline
Where in United States
Also in 2 other countries, 4 sites
- Albany Gastroenterology ConsultantsAlbany, United StatesContact: Agomab Clinical OperationsTaking people
- Synergy Healthcare LLCBradenton, United StatesContact: Agomab Clinical OperationsTaking people
- GI AllianceCedar Park, United StatesContact: Agomab Clinical OperationsTaking people
- GI Alliance - Fort WorthFort Worth, United StatesContact: Agomab Clinical OperationsTaking people
- Amel Med LLCGeorgetown, United StatesContact: Agomab Clinical OperationsTaking people
- University GastroenterologyProvidence, United StatesContact: Agomab Clinical OperationsTaking people
- GI AllianceSun City, United StatesContact: Agomab Clinical OperationsTaking people
About the trial
What the trial wants to find out
Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the efficacy, safety, and dose-response relationship of ontunisertib in participants with CD and symptomatic strictures, and contribute to the validation of novel endpoints to assess potential treatment benefit in patients with fibrostenosing Crohn's disease (FSCD).
Read full original descriptionShow less
The participants will be in the trial for a duration of up to 60 weeks, consisting of a 6-week screening period (with 2 screening visits), a 52-week treatment period, and a 2-week follow-up period. The visit frequency in the treatment period will be every 6 to 8 weeks.
The 4 groups in the trial
- Ontunisertib HighTreatment being tested
Ontunisertib high dose
Treatment: Ontunisertib
- Ontunisertib MediumTreatment being tested
Ontunisertib medium dose
Treatment: Ontunisertib
- Ontunisertib LowTreatment being tested
Ontunisertib low dose
Treatment: Ontunisertib
- PlaceboTreatment being tested
Matching placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients With Fibrostenosing Crohn's Disease
- Plain-language title
- Tests ontunisertib against placebo in adults with narrowed bowel from Crohn's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 October 2026